(Reuters) -Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on ...

Bristol Myers Squibb and Bain Capital launch a new biopharma firm focused on autoimmune disease treatments, starting with 5 ...

The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...

Bristol Myers Squibb is spinning off a fresh company armed with five autoimmune disease drugs and $300 million in Bain ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives, Dan Lynch, and ...

Discover Bristol-Myers Squibb's Q2 2025 earnings insights: 17% growth, new partnerships, and raised guidance signal strong performance and a ...

The biopharma spinoff will advance the development of its five investigational therapies designed to treat autoimmune disease.

Bristol Myers Squibb & Co (NYSE:BMY) reported second-quarter 2025 revenues of $12.27 billion, beating the consensus of $11.31 ...

US pharma major Bristol Myers Squibb and Bain Capital announced the creation of a new independent biopharmaceutical company ...

Princeton: Bristol Myers Squibb and Bain Capital have announced the formation of a new independent biopharmaceutical company, ...

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which will retain 20% equity in the new company.

Bain Capital and Bristol Myers Squibb have formed a new biopharmaceutical company focused on developing new therapies for autoimmune diseases. The newly formed company launches with a $300 million ...